PharmaSynth ASRegistered
Qualified audit opinion. 2025 report: Qualified.
Key figures
896 270 €+52,8%
Revenue 2025
+18,8%
Average annual growth 2019–2025
Ratios
202526,3%
Profit margin
36,9%
EBITDA margin
93,8%
Equity ratio
14×
Current ratio
18,4%
Return on equity
2916 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 198 786 € | 9 | 42 809 € |
| Q1 2026 | 131 408 € | 10 | 46 184 € |
| Q4 2025 | 226 815 € | 11 | 48 589 € |
| Q3 2025 | 76 881 € | 11 | 46 593 € |
| Q2 2025 | 205 836 € | 10 | 39 265 € |
| Q1 2025 | 231 372 € | 9 | 47 436 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2019–2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||
| Total current assets | 213 484 | 398 964 | 588 770 | 635 684 | 783 422 | 968 754 | 1 183 550 |
| Total non-current assets | 25 598 | 38 269 | 90 310 | 197 667 | 157 357 | 154 963 | 185 367 |
| Total assets | 239 082 | 437 233 | 679 080 | 833 351 | 940 779 | 1 123 717 | 1 368 917 |
| Balance sheet — liabilities and equity | |||||||
| Current liabilities | 45 479 | 55 728 | 49 756 | 82 591 | 44 535 | 75 325 | 84 409 |
| Non-current liabilities | 11 239 | 0 | — | — | — | — | — |
| Total liabilities | 56 718 | 55 728 | 49 756 | 82 591 | 44 535 | 75 325 | 84 409 |
| Share capital | 60 908 | 60 908 | 60 908 | 60 908 | 57 180 | 57 180 | 57 180 |
| Retained earnings of previous periods | 72 485 | 115 365 | 314 506 | 562 325 | 687 489 | 832 973 | 985 121 |
| Profit for the year | 42 880 | 199 141 | 247 819 | 121 436 | 145 484 | 152 148 | 236 116 |
| Reserves and other equity | 6091 | 6091 | 6091 | 6091 | 6091 | 6091 | 6091 |
| Total equity | 182 364 | 381 505 | 629 324 | 750 760 | 896 244 | 1 048 392 | 1 284 508 |
| Income statement | |||||||
| Sales revenue | 319 371 | 444 406 | 510 772 | 475 618 | 635 352 | 586 714 | 896 270 |
| Operating profit | 42 713 | 204 183 | 238 881 | 113 814 | 153 209 | 128 395 | 289 216 |
| EBITDA | 53 644 | 217 749 | 257 817 | 140 324 | 204 231 | 168 670 | 330 919 |
| Profit before income tax | 42 880 | 199 141 | 247 819 | 121 436 | 145 484 | 152 148 | 236 116 |
| Profit for the reporting year | 42 880 | 199 141 | 247 819 | 121 436 | 145 484 | 152 148 | 236 116 |
| Labour costs | 180 026 | 156 011 | 176 627 | 222 785 | 297 674 | 373 405 | 422 547 |
| Depreciation of non-current assets | 10 931 | 13 566 | 18 936 | 26 510 | 51 022 | 40 275 | 41 703 |
| Other indicators | |||||||
| Employees | 8 | 7 | 7 | 7 | 7 | 8 | 9 |
| Calculated dividend | — | 0 | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
Click a node to see its other connections.
CompanyPersonShareholderOther roleAdditional link
Annual reportsPDF, XBRL
Loading list of reports…
Source: e-Business Register (RIK). Files open/download directly from the official register.
Related companies
Same activity — Põhifarmaatsiatoodete tootmine